CXChang Xu

Chang Xu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Chang Xu has a total of 212 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Time-to-expiration for evidence bodies of medication harms (TIME): survival analysis from a retrospective cohort

    by Xinyi Wang, Luis Furuya-Kanamori, Suhail A. Doi, Zhichun Gu, Yoon Loke, Sheyu Li, Evan Mayo-Wilson, Lifeng Lin, Su Golder, Haitao Chu, et al.

  • Toward Evidence Synthesis of Adverse Events in Imbalanced Time‐to‐Event Data

    by Zhen Peng, Jingyi Jiang, Lifeng Lin, Luis Furuya‐Kanamori, Sheyu Li, Yoon Loke, Haitao Chu, Sunita Vohra, Chang Xu

    Background: The routine approach in evidence synthesis of adverse events is to estimate the odds ratio or risk ratio of each individual study and then synthesize the study‐specific effects for a pooled average estimate, while seldom consider the potential imbalanced duration of exposures of study arms. This article aims to investigate the potential impact of imbalanced exposure time on harm effects. Methods: We simulated individual participant time‐to‐event data based on Cox proportional hazard model, with Weibull function to reshape the distribution of the hazards. We further collapsed the data into aggregated one and fitting both hierarchical Binomial regression model and hierarchical Poisson regression model to estimate the pooled RR and incidence rate ratio (IRR). The percentage bias, mean squared error, and coverage probability were examined. Results: Our results suggested that imbalanced exposure time between study arms can have substantial impact on the estimation of harm effects in evidence synthesis, especially when the extent of the imbalance exceeds 20%. Estimating an IRR to address the imbalanced exposure time only made sense for non‐recurrent events when the between‐study heterogeneity is small or moderate. A case study by 22 ongoing trials verified the potential biased estimation when exposure time was imbalanced between study arms. Conclusions: It is inappropriate to ignoring exposure time when there is a large difference (> 20%) between study arms; while the IRR could be used in some cases, collecting individual participant data for evidence synthesis of adverse events for time‐to‐event data should be the primary consideration.

  • Evaluating data extraction error by a large language model from randomised controlled trials: a large-scale empirical study

    by Shiqi Fan, Ming Chen, Suhail A Doi, Zhangnan Ye, Zhen Peng, Yuan Tian, Chengzhi Zhang, Luis Furuya-Kanamori, Lifeng Lin, Evan Mayo-Wilson, et al.

    Objective: To examine the potential errors of a general large language model (LLM) (ie, Claude 3.5 Sonnet) on data extraction from randomised controlled trials (RCTs). Design and setting: An empirical study comparing Claude 3.5 Sonnet extractions against a human-performed verification dataset. The extraction tasks for Claude 3.5 Sonnet were based solely on original RCT portable document format (PDF) files. For PDFs that could not be directly extracted by Claude 3.5 Sonnet, optical character recognition was employed to convert them into text format before extraction. Participants: A random sample of 664 trials was selected from a well-established trial bank and a final data pool was established based on rigorous manual cross-checking as a reference standard. Data sources: PubMed, EMBASE, Scopus, Web of Science (all databases) and the Cochrane Central Register of Controlled Trials (CENTRAL) up to February 2023. Eligibility criteria for selecting studies: RCTs on children involving medication and adverse events. Main outcome measures: Claude 3.5 Sonnet was applied to extract the basic information (eg, trial design, population information and source of funding) and adverse outcomes (ie, name of adverse events, number of events). Claude 3.5 Sonnet outputs were compared against the final data pool and all errors were recorded. Results are presented as error rates and with 95% CI, estimated using a generalised linear mixed model. Results: For the 664 trials, a total of 23 069 data cells were extracted via Claude 3.5 Sonnet, with 10 624 for basic information and 12 445 for adverse outcomes. The overall error rate for data extraction was 6.6% (95% CI 5.4% to 8.2%), with 5.7% (95% CI 5.2% to 6.1%) in basic information and 7.6% (95% CI 4.9% to 11.8%) in adverse outcomes. When stratified the 1542 total errors by error types, misallocation (assigning data to incorrect fields; 57.1%, 881/1542) and missed or omitted data (incomplete extraction of available data; 23.2%, 357/1542) accounted for the two most frequent errors, with misallocation occurring more in basic information (53.3%, 470/881), while missed or omitted data occurred more in adverse outcomes (96.1%, 343/357). Post hoc analysis examining the association between trial reporting quality (assessed using Consolidated Standards of Reporting Trials (CONSORT) 2025 and LLM data extraction error rates indicated that higher CONSORT adherence was associated with lower extraction error rates. Conclusions: The data extraction error of Claude was relatively low, but it alerts LLM applications in evidence synthesis. Detailed checking for LLM outputs should be the primary consideration for evidence synthesisers.


  • Unpublished trials affected evidence synthesis substantially when estimating medication harms in children

    by Zuhaer Yisha, Zhaohu Fan, Luis Furuya-Kanamori, Yuan Tian, Yoon Loke, Zhen Peng, Lifeng Lin, Su Golder, Haitao Chu, Sunita Vohra, et al.

  • Open Access

    Investigating the impact of problematic evidence on clinical practice guidelines and associated patient outcomes (VITALITY Study II): protocol

    by Chang Xu, Luis Furuya Kanamori, Hong Cao, Xinyi Wang, Yoon K Loke, Sheyu Li, Tianmeng Wen, Shiqi Fan, Zhichun Gu, Jennifer C Stone, et al.

    Introduction Increasing publication of fraudulent clinical trials poses a serious threat to evidence-based medicine. In the VITALITY Study I, we demonstrated that contamination by retracted trials significantly distorts evidence synthesis. The upcoming VITALITY Study II will take a step further and investigate how such problematic evidence undermines the credibility of guideline recommendations. Methods and analyses The VITALITY Study II will adopt a retrospective cohort design and will be structured as three work packages (WPs). To start with, a cohort of clinical practice guidelines (CPGs) that were contaminated by retracted trials and/or meta-analyses that included retracted trials will be established based on forward citation searching (WP1). Then, recommendations from these CPGs that used evidence from retracted trials and/or meta-analyses that synthesised these retracted trials will be re-evaluated after removing such problematic evidence, in terms of both the direction and strength of effect sizes (WP2). Finally, the subsequent impact on patient outcomes attributable to distorted recommendations will be estimated on a hypothetical population, measured by the number of expected benefit loss and the number of expected harm increment per 100 000 patients (WP3). Ethics and dissemination Formal ethical approval is not necessary for this study as it does not involve human or animal participants, nor does it involve the collection of primary data. We will disseminate the findings through publication in peer-reviewed journals and, whenever possible, presentations at academic conferences.

  • Evidence contamination: what it is and why it matters

    by Chang Xu, Luis Furuya-Kanamori, Zhichun Gu, Yoon Loke, Lifeng Lin, Jennifer Stone, Zhaohu Fan, Su Golder, Zongshi Qin, Xiaodong Guan, et al.

    Nevertheless, the growing concerns about research misconduct (see related terminologies in box 1) bring a new and serious challenge for this well-established system.18 19 During the past decades, retraction rates increased from 10.7 to 44.8 per 100 000 publications, with research misconduct accounting for the most (66.8%).20 Research misconduct can undermine the foundations of evidence-based decision-making: what seems to be the best available evidence may actually be fabricated or manipulated.21 If not properly addressed, the best available evidence may be distorted by fraudulent studies.22 Addressing this problem is challenging, as Grey et al pointed out, ‘retracting untrustworthy, problematic academic publications can take years, and most often never occurs’.23 However, this should not prevent us from taking the first step forward.


  • Open Access

    Time-to-retraction and likelihood of evidence contamination (VITALITY Extension I): a retrospective cohort analysis

    by Yuan Tian, Zhen Peng, Suhail A. R. Doi, Luis Furuya-Kanamori, Hong Cao, Lifeng Lin, Haitao Chu, Yoon Loke, Ben W. Mol, Su Golder, et al.

    Background: The number of problematic randomized clinical trials (RCTs) has risen sharply in recent decades, posing serious challenges to the integrity of the healthcare evidence ecosystem. Objective: To investigate whether retraction of problematic RCTs could reduce evidence contamination. Design: Retrospective cohort study Setting: A secondary analysis of the VITALITY Study database. Participants: 1,330 retracted RCTs with 847 systematic reviews. Measurements: The difference in the median number (and its interquartile, IQR) of contamination before and after retraction. The association between time-to-retraction and likelihood of evidence contamination. Results: Among these retracted RCTs, 426 led to evidence contamination, resulting in 1,106 contamination events (251 after retraction vs. 855 before retraction). The time interval between RCT publication and first contamination ranged from 0.2 to 30.9 years, with a median of 3.3 years (95% CI: 3.0 to 3.9). The median number of contaminated systematic reviews was lower after retraction than before retraction (0, IQR: 0 to 1 vs. 1, IQR: 1 to 2, P < 0.01). Compared with trials retracted more than 7.5 years after publication, those retracted between 1.0 and 1.8 years (OR = 0.70, 95% CI: 0.60 to 0.80) and retracted within 1.0 year (OR = 0.69, 95% CI: 0.60 to 0.80) were associated with lower likelihood of evidence contamination. Limitations: Only assessed contaminated systematic reviews with quantitative synthesis and limited to retracted RCTs. Conclusions: Retracting problematic RCTs can significantly reduce evidence contamination, and faster retraction was associated with less contamination. To safeguard the integrity of the evidence ecosystem, academic journals should act promptly in the retraction of problematic studies to minimize their downstream impact. Primary Funding Sources: The National Natural Science Foundation of China (72204003, 72574229)

  • Open Access

    The Trial Bank initiative to promote trustworthy living evidence for medication safety (PROMISE) of children: design and pilot validation

    by Chang Xu, Suhail A. Doi, Sunita Vohra, Luis Furuya-Kanamori, Yingxia Wang, Lijun Tang, Yuan Tian, Shiqi Fan, Zhen Peng, Evan Mayo-Wilson, et al.

    While medications are essential for preventing and treating disease, they can also cause harm. Evidence synthesis has been widely adopted for evaluating ha


  • Open Access

    Comparing the accuracy of AI-assisted data extraction versus human double extraction in evidence synthesis: a randomised controlled trial protocol

    by Zhen Peng, Shiqi Fan, Yuan Tian, Yingxia Wang, Zongshi Qin, Suhail Doi, Chang Xu

    Introduction: Traditional data extraction strategies, such as human double extraction, are both time consuming and labour-intensive. Artificial intelligence (AI) has emerged as a promising tool for facilitating data extraction. However, it is not yet suitable as a standalone solution. We will conduct a randomised controlled trial (RCT) to compare the efficiency and accuracy of the AI-human data extraction strategy with human double extraction. Methods and analysis: This study is designed as a randomised, controlled, parallel trial. Participants will be randomly assigned to either the AI group or the non-AI group at a 1:2 allocation ratio. The AI group will use a hybrid approach that combines AI extraction followed by human verification by the same participant, while the non-AI group will use human double extraction. Data will be collected for two tasks: event count and group size. Ten RCTs will be selected from an established database that analysed data extraction errors in systematic reviews of sleep medicine. The primary outcome measure will be the percentage of correct extractions by both groups for each data extraction task. Ethics and dissemination: The trial is approved by the Ethics Council of Anhui Medical University (No. 81250507). We plan to publish the main results as an academic publication in an international peer-reviewed journal in 2026. Trial registration number: Chinese Clinical Trial Register (Identifier: ChiCTR2500100393).


  • Accuracy of large language models in data extraction from randomized controlled trials in sleep medicine: A proof-of-concept study

    by Zhen Peng, Xingwei Wu, Zongshi Qin, Suhail A. Doi, Luis Furuya-Kanamori, Yi Hong, Lifeng Lin, Haitao Chu, Chang Xu, Mingkai Liu